17beta-estradiol and restenosis: a novel vaso-protective role for estrogen?
Restenosis is the major limitation of percutaneous transluminal coronary angioplasty. Several therapies to prevent restenosis, pharmacological and non-pharmacological, have shown favorable results in experiments, and a few in clinical trials. Evidence is accumulating that 17beta-estradiol, the predominant circulating form of estrogen in premenopausal women, inhibits neointimal formation following arterial injury. Evidence demonstrating the ability of estrogen to suppress neointimal formation and underlying mechanisms are reviewed.